Maxim Group set a $4.00 price target on AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on AEZS. HC Wainwright set a $3.00 price objective on AEterna Zentaris and gave the company a buy rating in a research note on Wednesday, November 29th. Zacks Investment Research downgraded AEterna Zentaris from a buy rating to a hold rating in a research note on Monday, January 15th.

Shares of AEterna Zentaris (NASDAQ AEZS) remained flat at $$2.28 during trading hours on Wednesday. 520,623 shares of the stock traded hands, compared to its average volume of 1,280,000. The company has a market capitalization of $37.13, a price-to-earnings ratio of -1.26 and a beta of 0.87. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $3.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). AEterna Zentaris had a negative net margin of 2,338.61% and a negative return on equity of 732.74%. research analysts anticipate that AEterna Zentaris will post -1.5 EPS for the current fiscal year.

A hedge fund recently raised its stake in AEterna Zentaris stock. JPMorgan Chase & Co. increased its position in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 56,800 shares of the biopharmaceutical company’s stock after buying an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned about 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent quarter. 2.01% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/20/aeterna-zentaris-aezs-given-a-4-00-price-target-at-maxim-group.html.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.